Eurofins Scientific SE ERF
Eurofins' €556m 'excess cash' earned just 1.42% vs banks' quoted ~2.88%, echoing the NMC Health fraud tell; only radical disclosure on cash, entities, and Dr. Martin's real estate can clear it.
Thesis
Muddy Waters flags a fresh red flag in its ongoing short campaign against Eurofins Scientific: the company's reported 2023 interest income of €7.9m on an average €556m 'excess cash' balance implies an effective rate of only 1.42%, versus the 2.10-3.68% quarterly rates Eurofins' own network banks disclosed at the Eurofins Cerep AGM — a shortfall of roughly €8m. The same interest-income anomaly was central to Muddy Waters' 2019 exposure of NMC Health as a fraud. The firm argues a 'cash audit' cannot resolve concerns given ~650,000 inter-company receivables across ~1,300 entities and unexplained linkages to Dr. Gilles Martin's private holding Analytical Bioventures, whose 2021-2023 financials remain unfiled. The remedy demanded is sweeping transparency: release former employees from NDAs and disclose every acquisition, wind-up, testing-segment P&L, and real-estate transaction involving Dr. Martin since 2015.
SCQA
Eurofins Scientific is a €60,000-employee, ~1,300-entity testing network that centralises cash via a pooling structure and reported €556m of average excess cash in 2023.
That excess cash earned only €7.9m of interest (1.42%), roughly half the 2.88% blended rate its own network banks told Cerep they were quoting — the same red flag Muddy Waters used to expose NMC Health in 2019.
Muddy Waters demands Eurofins release ex-employees from NDAs and disclose Analytical Bioventures' overdue financials, every acquisition and wind-up since 2015, segment P&L, and Dr. Martin's real-estate dealings.
No explicit price target; the payoff framed is validation of the short thesis — confirmation that reported cash may be overstated and governance compromised, implying material downside to Eurofins equity.
The three reasons
- 1
Eurofins' €556m avg excess cash earned only €7.9m (1.42%) vs expected ~2.88% on bank-quoted rates
- 2
Dr. Martin micromanages £20k oven buys and $100k hires yet 'overlooks' ~€8m of free interest income
- 3
Same interest-income shortfall pattern used by Muddy Waters to flag NMC Health fraud in 2019
Primary demands
- Release former employees from NDAs so they may speak with investors without legal threats
- File Analytical Bioventures S.C.A.'s overdue 2021-2023 consolidated financials
- Disclose all business acquisitions since 2015 with consideration, PPA, and pre/post financials
- Explain reasoning for each entity wound up, disposed of, or transferred since 2015
- Disclose revenue, EBITDA, compensation, and headcount by testing type and geography from 2015
- Disclose rent, deposits, improvements, square meterage, and holding-company names for each real estate site owned by Dr. Martin
- Disclose all vacant sites and all real estate acquisitions since 2020
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Precedents cited
- NMC Health PLC fraud exposure (Muddy Waters, 2019)
- Muddy Waters' prior Eurofins reports: 'Nothing but Net' (July 2024) and 'Optimized Malfeasance' (June 2024)
Notable slides (3)
Notes
Short 4-page forensic addendum in the Muddy Waters Eurofins short campaign — not a deck but a Word-style research note with a single quarter-by-quarter interest-rate table as its visual centrepiece. Anchor argument is a direct analogy to NMC Health (2019), where understated interest income on reported cash was the first crack. No price target or position size disclosed; the payoff framing is epistemic (validation of fraud suspicion) rather than quantitative. Closing ask is a 7-point transparency checklist rather than a single corporate action. Ticker 'ERF' used for Euronext Paris listing; the document references 'ALECR.FP' (Eurofins Cerep) as the source of the banks' rate disclosure.